Oasis Biosciences
This article was originally published in The Gray Sheet
Executive Summary
Series A private placement will provide a total of $7 mil. in funding, contingent upon certain milestones. The privately held San Diego developer of high-throughput target validation systems and single nucleotide polymorphism (SNP)-based diagnostics notes that the funds "will enable the company to expand its platform technology to address substantially larger numbers of candidate genes in much shorter time frames"